Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
Center for International Blood and Marrow Transplant Research
Study ID
NCT03127761
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Allogeneic Hematopoietic Stem Cell Transplant — OTHER
    This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.

Study Details

Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients. Thus, although potentially curative, standard risk MM patients have excellent prognoses in the era of novel therapies which reduces the overall benefit of alloHCT. However, because the outcomes for high-risk MM remain poor despite the best available standard therapies (overall survival of 24-36 months), initial data suggest that alloHCT should be explored in this subset.

Key Dates

Start date
Jul 25, 2017
Status verified
Aug 2023
Primary completion
May 31, 2027
Completion
Apr 30, 2028

Study Design

Enrollment
544 participants (estimated)

Arms

  • Arm: Allogeneic HCT
    Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
  • Arm: Historical autoHCT
    Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016

Primary Outcome Measure

Compare five-year survival [ Time Frame: 5 years post transplant ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Center for International Blood and Marrow Transplant ResearchMinneapolisMinnesota55401
Michael Tierney
[email protected]

Find similar trials in Minneapolis, MN

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Center for International Blood and Marrow Transplant Research· Minneapolis, MN

Related Studies